Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer

Expert Review of Anticancer Therapy

Volumn 2, Issue 4, 2002, Pages 417-425

  Zelek, Laurent ^a   Piedbois, Pascal ^a   Buyse, Marc ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Advanced colorectal cancer; Fluoropyrimidines; Meta analysis

Indexed keywords

ALPHA INTERFERON; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; ANTIDOTE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; RECOMBINANT INTERFERON;

ADVANCED CANCER; BOLUS INJECTION; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HEPATIC ARTERY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LIVER METASTASIS; MEDICAL ASSESSMENT; META ANALYSIS; METHODOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; COLORECTAL TUMOR; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; RISK; STATISTICAL ANALYSIS;

ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DATA INTERPRETATION, STATISTICAL; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON TYPE I, RECOMBINANT; LEUCOVORIN; META-ANALYSIS; METHOTREXATE; ODDS RATIO;

EID: 0036685326     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.4.417     Document Type: Review

References (52)

1. Considerations fbr the meta-analysis of randomized clinical trials. Summary of a panel discussion
2. Reporting, updating and correcting systematic reviews of the effects of healthcare
3. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
4. Meta-analysis of randomized trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer
5. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer
6. Efficacy of iv. continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
7. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer
8. Reporting results of cancer treatment
9. New guidelines to evaluate the response to treatment in solid tumors
10. Toxicity of 5-fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
11. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid
12. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil
13. Relationship of dUMP and free FdUMP pools to inhibition of thymidilate synthetase by 5-fluorouracil
14. The enhancement of 5-fluorouracil antimetabolic activity by leucovorin, menadione and α-tocopherol
15. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil
16. Methotrexate and fluorouracil following tamoxifen and premarin in advanced breast cancer
17. Antimetabolites
18. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites
19. Interaction of fluorouracil and interferon in human colon cancer cell lines: Cytotoxic and cytokinetic effects
20. Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors
21. Pharmacokinetics of the fluoropyrimides: Implications for their clinical use
22. Pharmacokinetics of 5-fluorouracil administered orally, by rapid iv. and by slow infusion
23. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules
24. Continuous iv. infusion chemotherapy
25. Intra-arterial infusion of anticancer drugs: Theoretic aspects of drug delivery and review of responses
26. Regional chemotherapy of neoplastic diseases
27. Comparison of oral capecitabine versus iv. fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized Phase III study
28. Oral capecitabine compared with iv. 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: Results of a large Phase III study
29. Relation between tumor response to firstline chemotherapy and survival in advanced colorectal cancer: A meta-analysis
30. Adjuvant therapy of colorectal cancer: Why we still don't know
31. Intravenous 5-FU/LV + CPT11 combined with hepatic arterial infusion pirarubicin in nonresectable liver metastases from colorectal cancer
32. The combination of estimates from different experiments
33. A general parametric approach to the meta-analysis of randomized clinical trials
34. Meta-analysis in clinical trials
35. Statistical aspects of the analysis of data from retrospective studies of diseases
36. The effects of Tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28 896 women
37. Portal vein infusion of cytotoxic drugs after colorectal cancer surgery: A meta-analysis of 10 randomized studies involving 4000 patients
38. Disturbed by meta-analysis?
39. Meta-Analyses, use and misuse
40. Overcoming the limitations of current meta-analysis of randomised controlled trials
41. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: The need for systematic overviews
42. Pharmacoeconomic implications of hepatic arterial infusion versus iv. chemotherapy for the treatment of liver metastases of colorectal cancer origin
43. Systemic treatment of early cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
44. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials
45. Potential and pitfalls of randomized clinical trials in cancer research
46. Meta-analyses based on published data are unreliable
47. Meta-analyses need time, collaboration and funding
48. Meta-analysis: Methods, strengths and weaknesses
49. Meta-analysis of randomised controlled trials: A concern for standards
50. Obtaining data from randomised controlled trials: How much do we need for reliable and informative meta-analyses?